Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.
Clinical Trial Grant
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Pfizer, Inc.
Start Date
September 1, 2014
End Date
December 31, 2026
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Pfizer, Inc.
Start Date
September 1, 2014
End Date
December 31, 2026